Home › NCT06831383
The STOP-HPV Scale Up Study
Who can join
Ages 9 to 17 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patient of participating practice * Well child care visit during the 12-month intervention period * No prior dose of HPV vaccine at the time of the well child care visit * Age-eligible Exclusion Criteria: * Prior dose of HPV vaccine
About the study
Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only ("STOP-HPV-Online" and 2) online provider communication training plus a Learning Collaborative, with performance feedback, attended by practice leads ("STOP-HPV-LC).
cer-related costs. It is recommended at ages 11-12 years routinely but can be given starting at ages 9-10 years. Despite having an effective vaccine, HPV vaccine initiation/completion rates in the U.S. were only at 76.8%/61.4% respectively in 2023 among 13-17 year olds; these rates are lower than the other recommended adolescent vaccines. Two key barriers are 1) suboptimal clinician communication to address parental concerns and 2) ineffective office systems causing missed vaccine opportunities.
What is being tested
- STOP-HPV-Online (behavioral)
- STOP-HPV-LC (behavioral)
Sponsor: University of California, Los Angeles · Participants: 100,000 · Started: Mar 30, 2026
Contact the study team
- Peter Szilagyi, MD, MPH · Phone: 310-206-6328
- Christina Albertin, PhD, MPH · Phone: 317-701-4926
Official record on ClinicalTrials.gov — NCT06831383
Locations in the U.S.
| Virginia | AMGA, Alexandria |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.